434 related articles for article (PubMed ID: 26720671)
1. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
[TBL] [Abstract][Full Text] [Related]
2. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
Wang S; Cang S; Liu D
J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706
[TBL] [Abstract][Full Text] [Related]
3. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
[TBL] [Abstract][Full Text] [Related]
4. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
6. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive
Takeda M; Nakagawa K
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609789
[TBL] [Abstract][Full Text] [Related]
7. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
11. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
12. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR in Lung Cancer: Current Standards and Developments.
Díaz-Serrano A; Gella P; Jiménez E; Zugazagoitia J; Paz-Ares Rodríguez L
Drugs; 2018 Jun; 78(9):893-911. PubMed ID: 29915896
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
15. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
[TBL] [Abstract][Full Text] [Related]
16. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.
Chuang JC; Salahudeen AA; Wakelee HA
Expert Opin Pharmacother; 2016; 17(7):989-93. PubMed ID: 26950414
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib for the treatment of patients with
Alsharedi M; Bukamur H; Elhamdani A
Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
[TBL] [Abstract][Full Text] [Related]
18. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
20. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
